NCMM Associate Investigators

NCMM aims to continue to develop its scientific and technological capabilities by establishing strong collaborative links with key scientists and research groups across Norway, thus facilitating translational networking.

NCMM’s Associate Investigators are drawn from a group of outstanding scientists who are based in Norway, with expertise compatible with NCMM’s research areas and who are interested in collaborating with NCMM. Associate Investigators contribute their expertise in molecular and translational medicine, and support newly recruited young NCMM Group Leaders and early-stage Associate Investigators through mentoring activities. 

NCMM Associate Investigators continue to work at their host institutions, but are credited an affiliation to NCMM and the Nordic EMBL Partnership for molecular medicine and are eligible to apply for seed-funding grants for collaborative projects with NCMM group leaders. In 2019, 4 million NOK seed money funding was made available for 11 new collaborative projects with NCMM group leaders.

NCMM has now entered its third five-year period (2020-2024), which has resulted in an evaluation of the Associate Investigator network. Evaluating the network allows for new Associate Investigators to join and also allows for an update of the scientific profile, by ensuring Associate Investigators' research interests match the renewed focus of NCMM and other molecular medicine environments. This evaluation also means that Associate Investigators continue to complement the expertise of current NCMM group leaders and the research taking place at the Centre.

All existing NCMM Associate and Young Associate Investigators were invited to apply for renewal to ensure that the research interests and focus of the Associate Investigator network remain relevant for all.

Call for new Associate Investigators opened in June 2020

Following an open call announced in June 2020, the applications for the status as NCMM Associate Investigator affiliated with NCMM and the Nordic EMBL Partnership in Molecular Medicine were evaluated by a Selection Committee. NCMM’s Associate Investigator network comprised of 34 scientists throughout its second five-year period. Based on applications for renewal, 21 Associate Investigators were re-appointed in the Spring of 2020. Including the Associate Investigators appointed in Fall 2020, the network now consists of 47 scientists from all over Norway. 

The reappointed and newly appointed NCMM Associate Investigators and Young Associate Investigators are as follows:

NCMM Associate Investigators:

  • Professor Tero Aittokallio, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital (newly appointed Fall 2020)
  • Professor Ole A. Andreassen, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo (re-appointed)
  • Dr. Thomas Arnesen, Department of Molecular Biology, University of Bergen and Department of Surgery, Haukeland University Hospital (re-appointed)
  • Dr. Magnus Aronsen, Division of Physiology, Institute of Basic Medical Sciences, University of Oslo and Oslo University Hospital (newly appointed Fall 2020)
  • Dr. Lorena Arranz, Department of Medical Biology, University of Tromsø and Department of Hematology, University Hospital of Northern Norway (re-appointed)
  • Dr. Charlotte Boccara, Institute of Basic Medical Sciences, University of Oslo (newly appointed Fall 2020)
  • Professor Yvonne Böttcher, Department of Clinical Molecular Biology, Akershus University Hospital and Institute of Clinical Medicine, University of Oslo (newly appointed Fall 2020)
  • Associate Professor Simona Chera, Department of Clinical Science, University of Bergen (re-appointed)
  • Professor Rafal Ciosk, Section for Biochemistry and Molecular Biology, Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo (newly appointed Fall 2020)
  • Associate Professor Rune Enger, Institute of Basic Medical Sciences, University of Oslo (newly appointed Fall 2020) 
  • Professor Marianne Fyhn, Section for Physiology and Cell Biology, Department of Biosciences, University of Oslo (newly appointed Fall 2020)
  • Professor Joel Glover, Institute of Basic Medical Sciences, University of Oslo (newly appointed Fall 2020)
  • Associate Professor Victor Greiff, Institute of Clinical Medicine, University of Oslo (newly appointed Fall 2020)
  • Dr. Gunnveig Grødeland, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital (newly appointed Fall 2020)
  • Professor John-Bjarne Hansen, KG Jebsen – Thrombosis Research and Expertise Centre (TREC), Department of Clinical Medicine, University of Tromsø,  and University Hospital of Northern Norway (re-appointed)
  • Associate Professor Nils Halberg, The Department of Biomedicine, University of Bergen (re-appointed)
  • Professor Guttorm Haraldsen, Institute of Clinical Medicine, University of Oslo and Department of Pathology, Oslo University Hospital (newly appointed Fall 2020)
  • Dr. Helene Knævelsrud, Institute for Cancer Research, Oslo University Hospital and CanCell, University of Oslo (newly appointed Fall 2020)
  • Professor Arne Klungland, Department of Microbiology, Division of Diagnostics and Intervention, Oslo University Hospital and University of Oslo (re-appointed)
  • Professor Vessela Kristensen, Department of Medical Genetics, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo (newly appointed Fall 2020)
  • Professor Dirk Linke, Section for Genetics and Evolutionary Biology, University of Oslo (re-appointed)
  • Professor Karl-Johan Malmberg, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and University of Oslo (re-appointed)
  • Professor Hans-Peter Marti, Department of Medicine, Haukeland University Hospital, University of Bergen (newly appointed Fall 2020)
  • Professor Hilde L. Nilsen, Department of Clinical Molecular Biology, Akershus University Hospital and University of Oslo (re-appointed)
  • Professor Ragnhild A. Lothe, Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital and University of Oslo (re-appointed)
  • Dr Alicia Llorente, Institute for Cancer Research, Oslo University Hospital (newly appointed Fall 2020)
  • Associate Professor Reidar Lund, Section for Chemical Life Sciences, Department of Chemistry, University of Oslo (re-appointed)
  • Dr. Espen Melum, Research Institute for Internal Medicine, Oslo University Hospital and University of Oslo (re-appointed)
  • Professor Emmet McCormack, Department of Clinical Science, University of Bergen (newly appointed Fall 2020) 
  • Associate Professor June Myklebust, Institute for Cancer Research, Oslo University Hospital and Institute for Clinical Medicine, University of Oslo (newly appointed Fall 2020)
  • Professor Pål R. Njølstad, KG Jebsen Center for Diabetes Research, University of Bergen and Haukeland University Hospital (re-appointed)
  • Dr. Lynn Butler Odeberg, University of Tromsø and the Karolinska Institute (re-appointed
  • Professor Jacob Odeberg, Institute for Clinical Medicine, University of Tromsø and University Hospital of North Norway (newly appointed Fall 2020)
  • Professor Johanna Olweus, KG Jebsen Center for Cancer Immunotherapy, Department of Cancer Immunology, Institute for Cancer Research, University of Oslo and Oslo University Hospital (re-appointed)
  • Professor Cinzia Progida, Section for Physiology and Cell Biology, Department of Biosciences, University of Oslo (newly appointed Fall 2020)
  • Professor Christine Hanssen Rinaldo, Department of Clinical Medicine, University of Tromsø and University Hospital North Norway, (newly appointed Fall 2020)
  • Dr. Hege Russnes, Department of Pathology and Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital and University of Oslo (re-appointed)
  • Dr. Even Holth Rustad, Akershus University Hospital and Oslo University Hospital (newly appointed Fall 2020)
  • Associate Professor Axel Sandvig, Integrative Neuroscience Group, Department of Neuromedicine and Movement Science, NTNU (newly appointed Fall 2020)
  • Professor Anne Simonsen, Institute of Basic Medical Sciences, University of Oslo (re-appointed)
  • Professor Rolf Skotheim, Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital and University of Oslo (re-appointed)
  • Dr. Asbjørg Stray‐Pedersen, Norwegian National Unit for Newborn Screening, Oslo University Hospital and Institute for Clinical Medicine, University of Oslo (newly appointed Fall 2020)
  • Professor Kjetil Taskén, Institute for Cancer Research, Oslo University Hospital and University of Oslo (re-appointed)
  • Dr Alfonso Urbanucci, Dept. of Tumor Biology, Institute for Cancer Research, Oslo University Hospital (newly appointed Fall 2020)
  • Associate Professor Eivind Valen, Computational Biology Unit, Department of Informatics, University of Bergen (newly appointed Fall 2020)
  • Dr. Marc Vaudel, Department of Clinical Science, University of Bergen (newly appointed Fall 2020)
  • Professor Emre Yaksi, Kavli Institute for Systems Neuroscience/Centre for Neural Computation, Norwegian University of Science and Technology (NTNU) (re-appointed).
Published Dec. 19, 2016 7:28 PM - Last modified Apr. 27, 2021 11:17 AM